U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C31H25F3N2O4
Molecular Weight 546.5364
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of SLX-4090

SMILES

COC1=CC=CC(C(=O)NC2=CC=C3CN(CCC3=C2)C(=O)OC4=CC=CC=C4)=C1C5=CC=C(C=C5)C(F)(F)F

InChI

InChIKey=AZUIUVJESCFSLJ-UHFFFAOYSA-N
InChI=1S/C31H25F3N2O4/c1-39-27-9-5-8-26(28(27)20-10-13-23(14-11-20)31(32,33)34)29(37)35-24-15-12-22-19-36(17-16-21(22)18-24)30(38)40-25-6-3-2-4-7-25/h2-15,18H,16-17,19H2,1H3,(H,35,37)

HIDE SMILES / InChI

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Target ID: P55157
Gene ID: 4547.0
Gene Symbol: MTTP
Target Organism: Homo sapiens (Human)
8.0 nM [IC50]
Name Type Language
SLX-4090
Common Name English
2(1H)-ISOQUINOLINECARBOXYLIC ACID, 3,4-DIHYDRO-6-(((6-METHOXY-4'-(TRIFLUOROMETHYL)(1,1'-BIPHENYL)-2-YL)CARBONYL)AMINO)-, PHENYL ESTER
Systematic Name English
KD-026
Code English
PHENYL 6-((3-METHOXY-2-(4-(TRIFLUOROMETHYL)PHENYL)BENZOYL)AMINO)-3,4-DIHYDRO-1H-ISOQUINOLINE-2-CARBOXYLATE
Systematic Name English
Code System Code Type Description
CAS
913541-47-6
Created by admin on Sat Dec 16 01:41:13 GMT 2023 , Edited by admin on Sat Dec 16 01:41:13 GMT 2023
PRIMARY
PUBCHEM
53497429
Created by admin on Sat Dec 16 01:41:13 GMT 2023 , Edited by admin on Sat Dec 16 01:41:13 GMT 2023
PRIMARY
FDA UNII
F84YQX13FV
Created by admin on Sat Dec 16 01:41:13 GMT 2023 , Edited by admin on Sat Dec 16 01:41:13 GMT 2023
PRIMARY
CLINICAL_TRIALS.GOV
SLX-4090
Created by admin on Sat Dec 16 01:41:13 GMT 2023 , Edited by admin on Sat Dec 16 01:41:13 GMT 2023
PRIMARY Funding Source - FDA OOPDPurpose: This study is being done to find out whether an investigational (not approved by FDA ) drug called SLx-4090 or Orlistat (FDA approved medication for weight loss) when given alone or in combination can treat the high blood fat (elevated triglycerides)levels found in the condition Type 1 Hyperlipoproteinemia (T1HLP) better or more safely than low fat diet alone, the current standard medical care.It is also not clear whether Orlistat, that is FDA approved for weight loss, is effective in lowering blood fat levels in patients with Type 1 hyperlipoproteinemia (T1HLP). The researchers are interested in learning whether any one of these drugs when given alone or in combination is more effective and safe in treating T1HLP.
DRUG BANK
DB05678
Created by admin on Sat Dec 16 01:41:13 GMT 2023 , Edited by admin on Sat Dec 16 01:41:13 GMT 2023
PRIMARY